Hereditary Sensory Neuropathy Type 1 (HSN1) Overview

Save information for later
Sign Up

Learn About Hereditary Sensory Neuropathy Type 1 (HSN1)

What is the definition of Hereditary Sensory Neuropathy Type 1 (HSN1)?
Hereditary sensory neuropathy type 1 (HSN1) is a neurological condition characterized by nerve abnormalities in the legs and feet. Many people with this condition have tingling, weakness, and a reduced ability to feel pain and sense hot and cold. Some affected people do not lose sensation, but instead feel shooting pains in their legs and feet. As HSN1 progresses, sensory problems can affect the hands, arms, shoulders, and abdomen. In rare cases, people with this condition develop sensorineural hearing loss. HSN1 is caused by genetic changes in any of several genes, depending on the form of HSN1 (HSN1A is caused by genetic changes in the SPTLC1 gene; HSN1B is linked to a gene located in chromosome 3; HSN1C is caused by genetic changes in the SPTLC2 gene; HSN1D is caused by genetic changes in the ATL1 gene and HSN1E is caused by genetic changes in DNMT1 gene. All forms of HSN1 are inherited in an autosomal dominant manner.
What are the alternative names for Hereditary Sensory Neuropathy Type 1 (HSN1)?
  • Hereditary sensory neuropathy type 1
  • HSAN 1
  • HSN1
  • Hereditary sensory and autonomic neuropathy type 1
  • Neuropathy hereditary sensory and autonomic type 1
  • Neuropathy hereditary sensory radicular, autosomal dominant
Who are the top Hereditary Sensory Neuropathy Type 1 (HSN1) Local Doctors?
Elite in Hereditary Sensory Neuropathy Type 1 (HSN1)
Thorsten Hornemann
Elite in Hereditary Sensory Neuropathy Type 1 (HSN1)
Thorsten Hornemann
Zurich, ZH, CH 

Thorsten Hornemann practices in Zurich, Switzerland. Mr. Hornemann is rated as an Elite expert by MediFind in the treatment of Hereditary Sensory Neuropathy Type 1 (HSN1). His top areas of expertise are Hereditary Sensory Neuropathy Type 1 (HSN1), Hereditary Sensory and Autonomic Neuropathy Type 2, Hajdu-Cheney Syndrome, Anhidrosis, and Gastric Bypass.

Elite in Hereditary Sensory Neuropathy Type 1 (HSN1)
Dr. Florian S. Eichler
Neurology
Elite in Hereditary Sensory Neuropathy Type 1 (HSN1)
Dr. Florian S. Eichler
Neurology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Florian Eichler is a Neurologist in Boston, Massachusetts. Dr. Eichler is rated as an Elite provider by MediFind in the treatment of Hereditary Sensory Neuropathy Type 1 (HSN1). His top areas of expertise are Adrenoleukodystrophy (ALD), CACH Syndrome, Tay-Sachs Disease, Gangliosidosis, and Gastrostomy. Dr. Eichler is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Hereditary Sensory Neuropathy Type 1 (HSN1)
Dr. Michael E. Shy
Neurology
Elite in Hereditary Sensory Neuropathy Type 1 (HSN1)
Dr. Michael E. Shy
Neurology

State University Of Iowa

200 Hawkins Dr, 
Iowa City, IA 
319-356-1616
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Shy is a Neurologist in Iowa City, Iowa. Dr. Shy is rated as an Elite provider by MediFind in the treatment of Hereditary Sensory Neuropathy Type 1 (HSN1). His top areas of expertise are Charcot-Marie-Tooth Disease, Hereditary Sensory Neuropathy Type 1 (HSN1), Sensorimotor Polyneuropathy, and Septic Arthritis. Dr. Shy is currently accepting new patients.

View All Doctors
What are the latest Hereditary Sensory Neuropathy Type 1 (HSN1) Clinical Trials?
A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors
A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors
Who is this study for: Patients with glioblastoma multiforme and brain metastases from solid tumors
Enrollment Status: Recruiting
Publish Date: November 07, 2025
Intervention Type: Radiation, Drug
Study Drug: AZD1390
Study Phase: Phase 1

Summary: This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy

Match to trials
Find the right clinical trials for you in under a minute
Get started
Natural History of Familial Dysautonomia
Natural History of Familial Dysautonomia
Enrollment Status: Recruiting
Publish Date: November 07, 2025

Summary: The study will collect clinical information from patients with FD and allow them to give blood to help develop biological markers of the disease to aid diagnosis and treatment. This is a non-invasive, non-interventional, observation study that poses only minimal risk for participants. The study will document the clinical features of patients with FD overtime by storing their routine clinical test ...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center